arrow
J

Jordi Esteve

Hospital Clínic de Barcelona
H指数:68
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rapid molecular screening of adult AML : Experience from the Spanish CETLAM cooperative group

成人AML快速分子筛查:西班牙CETLAM合作组经验

2026-10-140
PRE
Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

更正:费城染色体阳性急性淋巴细胞白血病合并附加细胞遗传学异常的移植结局:欧洲血液与骨髓移植学会急性白血病工作组的研究

2026-08-310
OAAI
Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities

携带附加细胞遗传学异常的费城染色体阳性急性淋巴细胞白血病的移植结果

2026-07-130
OAAI
Outcomes of 544 Patients with t(6;9)/DEK::NUP214 acute myeloid leukemia undergoing allogeneic stem cell transplantation: an EBMT study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)

544例t(6;9)/DEK::NUP214急性髓系白血病患者行异基因干细胞移植的结局:欧洲血液和骨髓移植组急性白血病工作组(ALWP)和儿科疾病工作组(PDWP)的代表性研究

2026-04-220
PRE
The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations

DNMT3A基因突变对接受首次缓解期异基因移植的AML患者生存的影响,取决于核型及共现突变。

2025-12-230
PRE
Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party

供者选择对不良风险AML接受造血细胞移植的影响:EBMT急性白血病工作组的研究

2025-11-290
PRE
Impact of Wilms’ tumor 1 gene (WT1) mutation on outcome of allogeneic hematopoietic-cell transplantation for acute myeloid leukemia: a retrospective multicenter cohort study from the ALWP/EBMT registry

WT1基因突变对急性髓系白血病异基因造血细胞移植结局的影响:一项来自ALWP/EBMT注册中心的回顾性多中心队列研究

2025-10-160
OA
A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias

一种靶向CD84的新型嵌合抗原受体T细胞疗法,用于治疗急性髓系和T细胞淋巴母细胞白血病

Leukemia
IF13.4
2025-08-060
OAAI
Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain

enasidenib作为IDH2突变型急性髓系白血病的治疗:西班牙早期准入计划的多中心真实世界研究

2025-07-120
OAAI
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS

一项关于JNJ-74856665(二氢乳清酸脱氢酶抑制剂)单药或联合用药治疗AML或MDS患者的1期、首次人体试验、剂量递增研究

2025-07-010
OA
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations

可测量残留病灶(MRD)对维奈克拉与表观遗传学药物联合治疗急性髓系白血病患者的预后价值:ELN-2021 MRD建议的验证

2025-05-140
OA
Frailty assessment and outpatient pre-habilitation for adults undergoing allogeneic hematopoietic cell transplantation

老年评估和门诊预康复训练用于接受异基因造血细胞移植的成人

2025-04-080
PRE
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

异基因造血细胞移植(Allo-HCT)精炼的ELN 2022风险分类:西班牙造血细胞移植组(GETH-TC)中AML患者接受异基因造血细胞移植时不良风险组(Adverse-Plus)的验证

2025-03-210
OA
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

异基因造血细胞移植在具有骨髓增生异常相关遗传特征的急性髓系白血病患者中的应用:遗传基础分型的相关性。代表EBMT急性白血病工作组的回顾性分析

2025-03-101
PRE
Development and Validation of a Machine Learning Model for the Prediction of Bloodstream Infections in Patients with Hematological Malignancies and Febrile Neutropenia

恶性血液病伴发热性中性粒细胞减少症患者血流感染预测的机器学习模型的建立与验证

2024-12-280
OA
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations

Bleximenib剂量优化及携带KMT2A和NPM1基因变异的复发/难治性急性白血病患者1期研究的RP2D确定

BLOOD
IF23.1
2024-11-055
PRE
Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

可测量残留病灶(MRD)在联合维奈克拉和表观遗传学抑制剂治疗的AML治疗中的预后价值:ELN 2021年MRD建议的验证

BLOOD
IF23.1
2024-11-050
PRE
Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

挑战不良标签:急性髓系白血病患者在首次缓解期接受 allo-HCT 时,ELN 2022 不良细胞遗传学亚组的不同结局:代表 EBMT 急性白血病工作组。

BLOOD
IF23.1
2024-11-050
PRE